The role of new asthma treatments

Allergology International

Volumn 47, Issue 4, 1998, Pages 237-246

  Chung, K F ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Asthma; Corticosteroids; Eosinophils; Treatments; adrenergic agonists

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYTOKINE; INTERLEUKIN 10; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NEDOCROMIL; THEOPHYLLINE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHUS HYPERREACTIVITY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; EOSINOPHIL; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SLOW RELEASE FORMULATION; T LYMPHOCYTE ACTIVATION; TARGET CELL;

EID: 0032410919     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1592.1998.00100.x     Document Type: Review

References (92)

1. British Thoracic Society. Guidelines for management of asthma in adults: I - chronic persistent asthma. Br. Med. J. 1990; 301: 651-3.
2. Woolcock A, Rubinfeld AR Seale JP et al. Asthma Management Plan, 1989. Med. J. Australia 1989; 151: 650-2.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/WHO workshop report. National Institutes of Health, 1995.
4. Rice JF, Weller PH. Comparison of fluticasone propionate and sodium cromoglycate for the treatment of childhood asthma (an open parallel group study). Respir. Med. 1995; 89: 363-8.
5. Price Jf. Inhaled corticosteroids: Clinical relevance of safety measures Pediatr. Pulmonol. Suppl. 1997; 15: 40-5.
6. Manolitsas ND, Wang J, Devalia J, Trigg CJ, McAulay AE, Davies RJ. Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. Am. J. Respir. Crit. Care Med. 1995; 151: 1925-2002.
7. Trigg CJ, Manolitsas ND, Wang J et al. Pacebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am. J. Respir. Crit. Care Med. 1994; 150: 17-22.
8. Laitinen LA, Laitinen A, Haahtele T. A comparative study of the effects of an inhaled corticosteroid, budesemide, and of a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma, J. Allergy Clin. Immunol. 1992; 90: 32-42.
9. Djukanovic R, Wilson JW, Britten KM et al. The effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis 1992; 145: 669-74.
10. Haahtela T, Jarvinen M, Kava T et al. Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma (see comments). N. Engl. J. Med. 1991; 325: 388-92.
11. Haahtela T, Jarvinen M, Kava T et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma (see comments). N Engl. J. Med. 1994; 331: 700-5.
12. Noonan M, Chervinsky P, Busse WW et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am. J. Respir. Crit. Care Med. 1995; 152: 1467-73.
13. Weiner P, Weiner M, Azgad Y. Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma. Thorax 1995; 50: 1270-3.
14. Malo JL, Cartier A, Ghezzo H, Trudeau C, Morris J, Jennings B Comparison of four-times-a-day and twice-a-day dosing regimens in subjects requiring 1200 micrograms or less of budesonide to control mild to moderate asthma. Respir. Med. 1995; 89: 537-43.
15. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J. Allergy Clin. Immunol. 1989; 84: 688-700.
16. Gaddie J, Petrie GR, Reid IW, Skinner C, Sinclair DJ, Palmer KN. Aerosol beclomethasone dipropionate: A dose - response study in chronic bronchial asthma. Lancet 1973; 2: 280-1.
17. Hummel S, Lehtonen L Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma (see comments). Lancet 1992; 340: 1483-7.
18. Dahl R, Lundback B, Malo JL et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest 1993; 104: 1352-8.
19. Boe J, Rosenhall L, Alton M et al. Comparison of dose - response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma. Allergy 1989; 44: 349-55.
20. Busse WW. Dose-related efficacy of Pulmicort (budesonide) Turbuhaler in moderate-to-severe asthma, J. Allergy Clin. Immunol. 1994; (Suppl.): 186 (Abstract).
21. Spitzer WO, Suissa S, Ernst P et al. The use of β-agonists and the risk of death and near death from asthma. N. Engl. J. Med. 1992; 326: 501-6.
22. Sears MR, Taylor RD, Pint CG et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-6.
23. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptomson existing inhaled corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-24.
24. Woolcock A, Lundback B, Rlngdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir Crit. Care Med. 1996; 153: 1481-8.
25. Pauwels RA, Lofdahl C, Postma D et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl. J. Med. 1997; 337: 1405-11.
26. Chung KF The complementary role of glucocorticosteroids and long-acting β-adrenergic agonists Allergy 1998; 53: 7-13.
27. Verberne AAPH, Frost C, Roorda RJ, Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am. J. Respir. Crit. Care Med. 1997; 156: 688-95.
28. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. Theophylline plus low dose inhaled steroid is as effective as high dose inhaled steroid in the control of asthma. New Eng. J. Med. 1997; 337: 1412-18.
29. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am. J. Respir. Crit. Care Med. 1995; 151: 1907-14.
30. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffrey P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343: 1006-8.
31. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderate severe asthma in children. Pediatrics 1993; 92: 64-77.
32. Meltzer EO, Orgel HA, Ellis EF, Eigen HN, Hemstreet MP. Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma, J. Allergy Clin. Immunol. 1992; 90: 2-11.
33. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: Potential breakthrough in asthma therapy. Eur. Respir. J. 1995; 8: 1203-13.
34. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204-219 on allergen-induced bronchoconstriction and airway hyper-reactivitiy in atopic subjects. Lancet 1991; 337: 690-4.
35. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-751, a potent leukotriene-D4 receptor antagonist. N Engl. J. Med. 1990; 323: 1736-39.
36. Spector SL, Smith LJ, Glass M. Effects of six weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am. J. Respir. Crit. Care Med. 1994; 150: 618-23.
37. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062-3.
38. Reiss TF, Sorkness CA, Stricker W et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997; 52: 45-8.
39. Vichow J, Hassall SM, Summerton L Improved asthma control over 6 weeks with Accolate (zafirlukast) in patients on high dose corticosteroids. Allergy 1997; 52: 183 (Abstract).
40. O'Shaughnessy KM, Wellings R, Gillies B, Fuller RW. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion (see comments). Am. Rev. Respir. Dis. 1993; 147: 1472-6.
41. Dworski R, Fitzgerald GA, Oates JA, Sheller JR Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am. J. Respir Crit. Care Med. 1994; 149: 953-9.
42. Tamaoki J, Kondo M, Sakai N et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am. J. Respir. Crit. Care Med. 1997; 155: 1235-40.
43. Cowburn AS, Sladek K, Soja J et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 1998; 101: 834-46.
44. In KH, Asano K, Beier D et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J. Clin. Invest. 1997; 99: 1130-7.
45. Chung KF. Management of difficult asthma (editorial). Br. J. Hosp. Med. 1994; 51: 80-1.
46. Barnes PJ, Chung KF. Difficult asthma: Cause for concern. Br. Med. J. 1989; 299: 695-8.
47. Wenzel SE, Szefler SJ, Leung DYM, Sloan SI, Rex MD, Martin RI Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 1997; 156: 737-43.
48. Woolcock AJ. Corticosteroid-resistant asthma. Definitions. Am. J. Respir. Crit. Care Med. 1996; 154: S45-8.
49. Barnes PJ, Adcock IM. Steroid resistance in asthma. Q.J.M. 1995; 88: 455-68.
50. Rosewicz S, McDonald AR, Maddux BA, Goldfine ID, Miesfeld RL, Logsdon CD. Mechanism of glucocorticoid receptor down-regulation by glucocorticoids. J. Biol. Chem 1988; 263: 2581-4.
51. Spahn JD, Leung DY Surs W, Harbeck RJ, Nimmagadda S, Szefler SJ Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am. J. Respir. Crit. Care Med. 1995; 151: 1709-14.
52. Nimmagadda SR Szefler SJ, Spahn JD, Surs W, Leung DY. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Am. J. Respir. Crit. Care Med. 1997; 155: 87-93.
53. Irusen E, Barnes PJ, Adcock IM, Chung KF. Altered affinity of dexamethasone for the glucocorticoid receptor (GR) in oral steroid-dependent asthmatics. Eur. Respir. J. 1998; in press (Abstract).
54. Kam JC, Szefler SJ, Surs W, Sher ER Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J. Immunol. 1993; 151: 3460-6.
55. Irusen E, Chung KF, Barnes PJ, Adcock IM. p38 mitogen-activated protein kinase mediates IL-2 and 4 changes in glucocorticoid receptor (GR) affinity. Eur. Respir. J. 1998; in press (Abstract).
56. Shiner RJ, Nunn AJ, Chung KF, Geddes DM. Randomized, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990; 336: 137-40.
57. Mullarkey MF, Blumenstein BA, Mandrade WP, Bailey GA, Olason I, Wetzel CE Methotrexate in the treatment of corticosteroid-dependent asthma. N. Engl. J. Med. 1988; 318: 683-7.
58. Alexander AG, Barnes NC, Kay AB. Cyclosporin A in corti-costeroid-dependent chronic severe asthma. Lancet 1992; 339: 324-7.
59. Nierop G, Gijzel WP, Bel EH, Zwinderman AH, Dijkman JH. Auranofin in the treatment of steroid dependent asthma: A double blind study. Thorax 1992; 47: 349-54.
60. Leach CL, Davidson P, Vanden Burgh J, Boudreau R Breath actuated MDI delivers 60% airway deposition with a new CFC-free beclomethasone formulation. Eur. Respir. J. 1996; 9: 255s (Abstract).
61. Sanderson CJ, Warren DJ, Strath M. Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures. J. Exp. Med. 1985; 162: 60-74.
62. Burke Gaffney A, Hellewell PG. Eotaxin stimulates eosinophil adhesion to human lung microvascular endothelial cells Biochem. Biophys. Res. Commun. 1996; 227: 35-40.
63. Mauser PJ, Pitman AM, Fernandez X et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am. J. Respir. Crit. Care Med. 1995; 152: 467-72.
64. Mauser PJ, Pitman A, Witt A et al. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Am. Rev. Respir. Dis. 1993; 148: 1623-7.
65. van Oosterhout AJM, Rudolf A, Ladenius C et al. Effect of anti-IL-5 and IL-5 in airway hyperreactivity and eosinophils in guinea pigs Am. Rev. Respir. Dis 1993; 147: 548-52.
66. Abraham WM, Sielczak MW, Ahmed A et al. Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J. Clin. Invest. 1994; 93: 776-87.
67. Collins PD, Griffiths-Johnson DA, Jose PJ, Williams TJ, Marleau S. Co-operation between interleukin-5 and the chemokine, eotaxin, to induce eosinophil accumulation in vivo, J. Exp. Med. 1995; 182: 1169-74.
68. Hisada T, Hellewell P, Teixeira MM, Malm MGK, Chung KF. Cooperative effects between eotaxin and interleukin-5 on airway hyperresponsiveness and eosinophil accumulation in the airways in mice. Am. d Respir. Crit. Care Med. 1998; 157: A700 (Abstract).
69. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder (see comments). Science 1997; 275: 77-9.
70. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J. Exp. Med. 1995; 182: 1527-36.
71. Kips JC, Brusselle GJ, Joos GF et al. Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice. Am. J. Respir. Crit. Care Med. 1996; 153: 535-9.
72. Lack G, Bradley KL, Hamelmann E et al. Nebulized IFN-gamma inhibits the development of secondary allergic responses in mice, J. Immunol. 1996; 157: 1432-9.
73. Zuany Amorim C, Leduc D, Vargaftig BB, Pretolani M. Modulation by rm interferon-gamma and CD4+ T-lymphocytes of allergic eosinophil accumulation in the mice peritoneal cavity. Ann. N. Y. Acad. Sci. 1994; 725: 34-43.
74. Naseer T, Minshall EM, Leung DY et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy Am. J. Respir. Crit. Care Med. 1997; 155: 845-51.
75. Kuchroo VK, Das MP, Brown JA et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/ Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995; 80: 707-18.
76. Burrows B, Martinez FD, Halonen M. Association of asthma with serum IgE levels and skin-test reactivity to allergens N. Engl. J. Med. 1989; 320: 271-2.
77. Sunyer J, Anto JM, Sabria J et al. Relationship between serum IgE and airway responsiveness in adults with asthma. J. Allergy Clin. Immunol. 1995; 95: 699-706.
78. Saban R, Haak Frendscho M, Zine M et al. Human FcERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J. Allergy Clin. Immunol. 1994; 94: 836-43.
79. Haak Frendscho M, Robbins K, Lyon R et al. Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immunology 1994; 82: 306-13.
80. Fahy JV, Fleming HE, Wong HH et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects (see comments). Am. J. Respir. Crit. Care Med. 1997; 155: 1828-34.
81. Boulet LP, Chapman KR, Cote J et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response (see comments). Am. J. Respir. Crit. Care Med. 1997; 155: 1835-40.
82. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin (see comments). N. Engl. J. Med. 1993; 329: 90-5.
83. Diamant Z, Timmers MC, Van der Veen H, Page CP, van der Meer FJ, Sterk PJ. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am. J. Respir. Crit. Care Med. 1996; 153: 1790-5.
84. Ahmed T Campo C, Abraham MK et al. Inhibition of antigen-induced acute bronchoconstriction, airway hyperresponsiveness, and mast cell degranulation by a non-anticoagulant heparin: Comparison with a low molecular weight heparin. Am. J. Respir. Crit. Care Med. 1997; 155: 1848-55.
85. John M, Lim S, Seybold J et al. Inhaled corticoteroids increase interleukin-10 but reduce macrophage inflammatory protein-1α, granulocyte-macrophage colony-stimulating factor and interferon-γ release from alveolar macrophages in asthma. Am. J. Respir. Crit. Care Med. 1998; 157: 256-63.
86. Zuany Amorim C, Creminon C, Nevers MC, Nahori MA, Vargaftig BB, Pretolani M. Modulation by IL-10 of antigen-induced IL-5 generation, and CD4+ T lymphocyte and eosinophil infiltration into the mouse peritoneal cavity. J. Immunol. 1996; 157: 377-84.
87. Zuany Amorim C, Haile S, Leduc D et al. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J. Clin. Invest. 1995; 95: 2644-51.
88. Chernoff AE, Granowitz EV, Shapiro L et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J. Immunol. 1995; 154: 5492-9.
89. Abbas AK, Williams ME, Burstein HJ, Chang TL, Bossu P, Lichtman AH. Activation and functions of CD4+ T-cell subsets. Immunol. Rev. 1991; 123: 5-22.
90. Watson ML, Smith D, Bourne AD, Thompson RC, Westwick J Cytokines contribute to airway dysfunction in antigen-challenged guinea pigs: Inhibition of airway hyperreactivity, pulmonary eosinophil accumulation, and tumor necrosis factor generation by pretreatment with an interleukin-1 receptor antagonist. Am. J. Respir. Cell Mol. Biol. 1993; 8: 365-9.
91. Barnes PJ, Adcock IM. Anti-inflammatory actions of steroids: Molecular mechanisms. Trends Pharmacol. Sci. 1993; 14: 436-41.
92. Heck S, Kullmann M, Gast A et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 1994; 13: 4087-95.